Form 8-K - Current report:
SEC Accession No. 0001610618-23-000106
Filing Date
2023-12-22
Accepted
2023-12-22 07:33:45
Documents
12
Period of Report
2023-12-22
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 CIDARA THERAPEUTICS, INC. FORM 8-K cdtx-20231222.htm   iXBRL 8-K 25276
  Complete submission text file 0001610618-23-000106.txt   153849

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20231222.xsd EX-101.SCH 1899
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20231222_lab.xml EX-101.LAB 25156
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20231222_pre.xml EX-101.PRE 13048
6 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20231222_htm.xml XML 2829
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 231507159
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)